Patch-Test Findings in 750 Soldiers Versus 1,800 Civilians
Doctor’s Notes · Life in Motion · Evidence Review
Editorial disclosure: The featured scene is an AI-created illustration of a fictional work, activity or research setting. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.
The question behind this paper
This review looks at military assignments and patch-test interpretation. The aim is to preserve the study’s actual population, denominator, design and timepoint so a useful signal does not become a universal claim.
Study snapshot
| Study element | Reported detail |
|---|---|
| Population | 750 soldiers and 1,800 civilians in Israel with suspected allergic contact dermatitis |
| Design | Retrospective multicenter comparative patch-test study |
| Timepoint | Clinical evaluation and relevant patch testing at presentation |
| Key result | At least one positive allergic reaction occurred in 27.73% of soldiers and 21.22% of civilians, a nonsignificant difference; occupationally related positives occurred in 29.32% versus 18.06% of positive reactors (p<.05). |
How to interpret the result
The overall positivity difference was not statistically significant, while occupational relevance differed among positive reactors. Those are separate denominators and should not be merged into a claim about all soldiers.
Important limitation: Both groups were selected because ACD was suspected, test panels followed clinical presentation, and occupational relevance was determined clinically rather than by population sampling.
Questionnaires, examinations, patch tests, chemical analyses and trial models answer different questions. A positive screening result, symptom report or association can guide a next step, but it does not diagnose the cause of one person’s rash. Clinician-directed testing is interpreted alongside timing, distribution and verified exposures.
Questions to ask next
- What exactly was measured: reported symptoms, visible signs, allergy, work loss, performance or quality of life?
- Which denominator applies to the quoted percentage: everyone invited, respondents, symptomatic people, examined participants or a selectively tested subgroup?
- Did the design compare groups or follow change over time, and what factors could still explain the difference?
- Would occupational-health review, clinician examination or clinician-directed testing change the practical plan?
- What requires prompt medical evaluation, including rapidly spreading redness, drainage, fever, severe pain, breathing symptoms or major loss of function?
Primary and authoritative sources
- Primary medical research record: PubMed PMID 37219963
- Authoritative guidance relevant to this topic
- American Academy of Dermatology: eczema skin-care guidance
PubMed indexing is not NIH endorsement of a study’s interpretation, this article or any product.
Where a cosmetic moisturizer fits
Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003, and outside research does not become a product result. #003 is not an eczema medicine and this article makes no treatment, cure, prevention, pediatric-safety or 24-hour claim.
Bottom line
The responsible conclusion is narrow: keep the population, denominator, comparator, timepoint and limitations attached, then use the evidence to ask better clinical and exposure-control questions rather than promise a universal result.